Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). Issa GC, Aldoss I, Thirman MJ, DiPersio J, et al. J Clin Oncol 2024 Aug 9:JCO2400826. doi: 10.1200/JCO.24.00826.

Read + Share

Amedeo Smart

Independent Medical Education

Issa GC, Aldoss I, Thirman MJ, DiPersio J, et al. Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). J Clin Oncol 2024 Aug 9:JCO2400826. doi: 10.1200/JCO.24.00826.
PMID: 39121437